Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares ...

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...